BACKGROUND: To develop a predictive genetic model of nicotine metabolism. UDP-glucuronosyltransferase-2B10 (UGT2B10) is the primary catalyst of nicotine glucuronidation. MATERIALS AND METHODS: The conversion of deuterated (D2)-nicotine to D2-nicotine-glucuronide, D2-cotinine, D2-cotinine-glucuronide, and D2-trans-3'-hydroxycotinine were quantified in 188 European Americans, and the contribution of UGT2B10 genotype to variability in first-pass nicotine glucuronidation assessed, following a procedure previously applied to nicotine C-oxidation. The proportion of total nicotine converted to nicotine-glucuronide [D2-nicotine-glucuronide/(D2-nicotine+D2-nicotine-glucuronide+D2-cotinine+D2-cotinine-glucuronide+D2-trans-3'-hydroxycotinine)] was the primary phenotype. RESULTS: The variant, rs61750900T (D67Y) (minor allele frequency=10%), is confirmed to abolish nicotine glucuronidation activity. Another variant, rs112561475G (N397D) (minor allele frequency=2%), is significantly associated with enhanced glucuronidation. rs112561475G is the ancestral allele of a well-conserved amino acid, indicating that the majority of human UGT2B10 alleles are derived hypomorphic alleles. CONCLUSION: CYP2A6 and UGT2B10 genotype explain 53% of the variance in oral nicotine glucuronidation in this sample. CYP2A6 and UGT2B10 genetic variants are also significantly associated with undeuterated (D0) nicotine glucuronidation in individuals smoking ad libitum. We find no evidence for further common variation markedly influencing hepatic UGT2B10 expression in European Americans.
BACKGROUND: To develop a predictive genetic model of n class="Chemical">nicotine metabolism. UDP-glucuronosyltransferase-2B10 (UGT2B10) is the primary catalyst of nicotine glucuronidation. MATERIALS AND METHODS: The conversion of deuterated (D2)-nicotine to D2-nicotine-glucuronide, D2-cotinine, D2-cotinine-glucuronide, and D2-trans-3'-hydroxycotinine were quantified in 188 European Americans, and the contribution of UGT2B10 genotype to variability in first-pass nicotine glucuronidation assessed, following a procedure previously applied to nicotine C-oxidation. The proportion of total nicotine converted to nicotine-glucuronide [D2-nicotine-glucuronide/(D2-nicotine+D2-nicotine-glucuronide+D2-cotinine+D2-cotinine-glucuronide+D2-trans-3'-hydroxycotinine)] was the primary phenotype. RESULTS: The variant, rs61750900T (D67Y) (minor allele frequency=10%), is confirmed to abolish nicotine glucuronidation activity. Another variant, rs112561475G (N397D) (minor allele frequency=2%), is significantly associated with enhanced glucuronidation. rs112561475G is the ancestral allele of a well-conserved amino acid, indicating that the majority of humanUGT2B10 alleles are derived hypomorphic alleles. CONCLUSION:CYP2A6 and UGT2B10 genotype explain 53% of the variance in oral nicotine glucuronidation in this sample. CYP2A6 and UGT2B10 genetic variants are also significantly associated with undeuterated (D0) nicotine glucuronidation in individuals smoking ad libitum. We find no evidence for further common variation markedly influencing hepatic UGT2B10 expression in European Americans.
Authors: F Patterson; R A Schnoll; E P Wileyto; A Pinto; L H Epstein; P G Shields; L W Hawk; R F Tyndale; N Benowitz; C Lerman Journal: Clin Pharmacol Ther Date: 2008-04-02 Impact factor: 6.875
Authors: Nancy L Saccone; Jen C Wang; Naomi Breslau; Eric O Johnson; Dorothy Hatsukami; Scott F Saccone; Richard A Grucza; Lingwei Sun; Weimin Duan; John Budde; Robert C Culverhouse; Louis Fox; Anthony L Hinrichs; Joseph Henry Steinbach; Meng Wu; John P Rice; Alison M Goate; Laura J Bierut Journal: Cancer Res Date: 2009-08-25 Impact factor: 12.701
Authors: Krishna R Veeramah; Mark G Thomas; Michael E Weale; David Zeitlyn; Ayele Tarekegn; Endashaw Bekele; Nancy R Mendell; Elizabeth A Shephard; Neil Bradman; Ian R Phillips Journal: Pharmacogenet Genomics Date: 2008-10 Impact factor: 2.089
Authors: Gang Chen; Andrea S Blevins-Primeau; Ryan W Dellinger; Joshua E Muscat; Philip Lazarus Journal: Cancer Res Date: 2007-10-01 Impact factor: 12.701
Authors: Sharon E Murphy; Peter Villalta; Sing-Wei Ho; Linda B von Weymarn Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2007-06-29 Impact factor: 3.205
Authors: Robert A Schnoll; Freda Patterson; E Paul Wileyto; Rachel F Tyndale; Neal Benowitz; Caryn Lerman Journal: Pharmacol Biochem Behav Date: 2008-10-31 Impact factor: 3.533
Authors: Yesha M Patel; Daniel O Stram; Lynne R Wilkens; Sung-Shim L Park; Brian E Henderson; Loic Le Marchand; Christopher A Haiman; Sharon E Murphy Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-10-07 Impact factor: 4.254
Authors: James W Baurley; Christopher S McMahan; Carolyn M Ervin; Bens Pardamean; Andrew W Bergen Journal: Trends Mol Med Date: 2018-02-04 Impact factor: 11.951
Authors: A M Teitelbaum; S E Murphy; G Akk; T B Baker; A Germann; L B von Weymarn; L J Bierut; A Goate; E D Kharasch; A J Bloom Journal: Pharmacogenomics J Date: 2017-03-14 Impact factor: 3.550
Authors: Jennifer J Ware; Xiangning Chen; Jacqueline Vink; Anu Loukola; Camelia Minica; Rene Pool; Yuri Milaneschi; Massimo Mangino; Cristina Menni; Jingchun Chen; Roseann E Peterson; Kirsi Auro; Leo-Pekka Lyytikäinen; Juho Wedenoja; Alexander I Stiby; Gibran Hemani; Gonneke Willemsen; Jouke Jan Hottenga; Tellervo Korhonen; Markku Heliövaara; Markus Perola; Richard J Rose; Lavinia Paternoster; Nic Timpson; Catherine A Wassenaar; Andy Z X Zhu; George Davey Smith; Olli T Raitakari; Terho Lehtimäki; Mika Kähönen; Seppo Koskinen; Timothy Spector; Brenda W J H Penninx; Veikko Salomaa; Dorret I Boomsma; Rachel F Tyndale; Jaakko Kaprio; Marcus R Munafò Journal: Sci Rep Date: 2016-02-01 Impact factor: 4.379
Authors: Gissela Borrego-Soto; Yadira X Perez-Paramo; Gang Chen; Sandra K Santuario-Facio; Jesus Santos-Guzman; Rodolfo Posadas-Valay; Fatima M Alvarado-Monroy; Isaias Balderas-Renteria; Ramses Medina-Gonzalez; Rocio Ortiz-Lopez; Philip Lazarus; Augusto Rojas-Martinez Journal: Pharmacogenomics J Date: 2020-01-21 Impact factor: 3.550